OC
QTTB icon

Oppenheimer & Co’s Q32 Bio QTTB Stock Holding History

Oppenheimer & Co’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,000
Closed -$19.4K – 1746
2025
Q2 		$19.4K Buy
+13,000
New +$22.2K ﹤0.01% 1595

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
TOCUITCONY
Trustees of Columbia University in the City of New York New York $891M AUM 17.3% 1-Year Est. Return

Oppenheimer & Co's QTTB Position: Q3 2025 in Review

Oppenheimer & Co sold out of Q32 Bio (QTTB) in Q3 2025, closing a stake of 13,000 shares — an estimated $19.4K sold.

Oppenheimer & Co first reported a position in QTTB in Q2 2025 and held it in 1 quarter. The position peaked at $19.4K in Q2 2025. 53 funds tracked by Wall St. Rank hold QTTB as of Q3 2025.

  • Oppenheimer & Co reported no remaining Q32 Bio position as of Q3 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 13,000 Q32 Bio shares in Q3 2025, an estimated $19.4K.
  • Oppenheimer & Co first reported a position in Q32 Bio in Q2 2025 and held it in 1 quarter.
  • Oppenheimer & Co's Q32 Bio position peaked at $19.4K in Q2 2025.
  • 53 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2025.

Based on Oppenheimer & Co's 13F filing for Q3 2025, filed 6 Nov 2025.